Nucleus Formulation Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 11-07-2024
- Paid Up Capital ₹ 5.00 M
as on 11-07-2024
- Company Age 15 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.57 Cr
as on 11-07-2024
- Satisfied Charges ₹ 5.83 Cr
as on 11-07-2024
- Revenue 25.35%
(FY 2022)
- Profit 485.44%
(FY 2022)
- Ebitda 53.22%
(FY 2022)
- Net Worth 40.66%
(FY 2022)
- Total Assets -27.46%
(FY 2022)
About Nucleus Formulation
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹2.57 Cr. The company has closed loans amounting to ₹5.83 Cr, as per Ministry of Corporate Affairs (MCA) records.
Dipesh Thakar and Jitendra Patel serve as directors at the Company.
- CIN/LLPIN
U24239GJ2009PTC057517
- Company No.
057517
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Jul 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Gandhi Nagar, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Nucleus Formulation?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dipesh Thakar  | Director | 13-Jul-2009 | Current |
| Jitendra Patel | Director | 13-Jul-2009 | Current |
Financial Performance of Nucleus Formulation.
Nucleus Formulation Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 25.35% increase. The company also saw a substantial improvement in profitability, with a 485.44% increase in profit. The company's net worth Soared by an impressive increase of 40.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nucleus Formulation?
Unlock access to Nucleus Formulation's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 28 Jul 2023 | ₹5.26 M | Open |
Others Creation Date: 06 Jun 2023 | ₹2.00 Cr | Open |
Hdfc Bank Limited Creation Date: 24 Jun 2021 | ₹0.40 M | Open |
How Many Employees Work at Nucleus Formulation?
Nucleus Formulation has a workforce of 14 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nucleus Formulation, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nucleus Formulation's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
